UroGen Pharma (URGN) Misses Q4 EPS by 17c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. CDNS
4. ANT
5. SPY
6. META
7. BA
8. INTC
9. JBLU
10. HOOD

Go back to UroGen Pharma (URGN) Misses Q4 EPS by 17c

UroGen Pharma Reports First Quarter 2020 Financial Results and Recent Corporate Developments

May 7, 2020 8:00 AM EDT

Received U.S. FDA Approval for Jelmyto, the First and Only Non-Surgical Treatment for Patients with Low-Grade Upper Tract Urothelial Cancer (LG-UTUC)

Jelmyto Launch on Track for June 1, 2020

Reported UGN-102 Phase 2b Trial Interim Data with 65% Complete Response at Three Months and 85% Durability at Nine Months in Low-Grade Non-Muscle Invasive Bladder Cancer

Conference Call and Webcast to be held Today at 8:30 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company... More